Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
11
MED Quote, Financials, Valuation and Earnings
Last price:
$10.69
Seasonality move
:
14.59%
Day range:
$10.36 - $10.75
52-week range:
$10.10 - $15.46
Dividend yield:
0%
P/E ratio:
516.75x
P/S ratio:
0.31x
P/B ratio:
0.59x
Volume:
150.8K
Avg. volume:
241.8K
1-year change:
-24.74%
Market cap:
$117.7M
Revenue:
$385.8M
EPS (TTM):
-$1.70
Analysts' Opinion
-
Consensus RatingMedifast, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.00, Medifast, Inc. has an estimated upside of 12.05% from its current price of $10.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $10.71.
Fair Value
-
According to the consensus of 1 analyst, Medifast, Inc. has 12.05% upside to fair value with a price target of $12.00 per share.
MED vs. S&P 500
-
Over the past 5 trading days, Medifast, Inc. has overperformed the S&P 500 by 0.7% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Medifast, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Medifast, Inc. revenues have been falling on a year-over-year basis for 14 quarters in a row. In the most recent quarter Medifast, Inc. reported revenues of $75.1M.
Earnings Growth
-
Medifast, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Medifast, Inc. reported earnings per share of -$1.65.
Enterprise value:
-38.9M
EV / Invested capital:
-0.19x
Price / LTM sales:
0.31x
EV / EBIT:
-36.82x
EV / Revenue:
-0.10x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-31.11x
Price / Operating cash flow:
94.30x
Enterprise value / EBITDA:
-1,295.41x
Gross Profit (TTM):
$275.2M
Return On Assets:
-6.83%
Net Income Margin (TTM):
-4.84%
Return On Equity:
-8.89%
Return On Invested Capital:
-8.36%
Operating Margin:
-10.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $602.5M | $385.8M | $119M | $75.1M | |
| Gross Profit | $775.9M | $444.6M | $275.2M | $88.2M | $52.1M | |
| Operating Income | $126.4M | $2.9M | -$14.2M | $709K | -$7.8M | |
| EBITDA | $144.1M | $21.4M | $30K | $8.6M | -$4.3M | |
| Diluted EPS | $9.11 | $0.19 | -$1.70 | $0.07 | -$1.65 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $306.9M | $222.8M | $224M | $214.4M | $201.7M | |
| Total Assets | $412.5M | $332.8M | $326.3M | $293.2M | $257M | |
| Current Liabilities | $169.8M | $140.9M | $92.3M | $64.2M | $43M | |
| Total Liabilities | $210M | $177.7M | $124.8M | $83.1M | $58.1M | |
| Total Equity | $202.5M | $155M | $201.5M | $210.1M | $198.9M | |
| Total Debt | $26M | $20.3M | $16.1M | $9.9M | $6.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $147.7M | $24.5M | $6.9M | -$4.9M | -$5.3M | |
| Cash From Investing | -$61M | -$26.5M | -$7.9M | -$19.4M | -$5M | |
| Cash From Financing | -$79.8M | -$1.5M | -$564K | -$1K | $1K | |
| Free Cash Flow | $141.2M | $17M | $1.2M | -$7.2M | -$6.6M | |
MED
Sector
Market Cap
$117.7M
$111.1M
Price % of 52-Week High
69.28%
73.71%
Dividend Yield
0%
0%
Shareholder Yield
1.5%
2.21%
1-Year Price Total Return
-24.74%
-2.83%
Beta (5-Year)
0.522
0.226
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.54
200-day SMA
Sell
Level
$12.66
Bollinger Bands (100)
Sell
Level
10.7 - 12.28
Chaikin Money Flow
Buy
Level
26.3M
20-day SMA
Sell
Level
$10.76
Relative Strength Index (RSI14)
Sell
Level
46.42
ADX Line
Sell
Level
9.79
Williams %R
Neutral
Level
-46.4865
50-day SMA
Sell
Level
$11.10
MACD (12, 26)
Sell
Level
-0.20
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Sell
Level
-27.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.1342)
Buy
CA Score
(Annual)
Level (0.9704)
Buy
Beneish M-Score
(Annual)
Level (-4.2643)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-2.0024)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Medifast, Inc. is a health and wellness company, which engages in the provision of habit-based and coach-guided lifestyle solutions called OPTAVIA. It offers and ships OPTAVIA products directly to its customers. It focuses on coaching healthy habits through a health transformational system. The company was founded by William Vitale in 1980 and is headquartered in Baltimore, MD.
Stock Forecast FAQ
In the current month, MED has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MED average analyst price target in the past 3 months is $12.00.
-
Where Will Medifast, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Medifast, Inc. share price will rise to $12.00 per share over the next 12 months.
-
What Do Analysts Say About Medifast, Inc.?
Analysts are divided on their view about Medifast, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Medifast, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Medifast, Inc.'s Price Target?
The price target for Medifast, Inc. over the next 1-year time period is forecast to be $12.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MED A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Medifast, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of MED?
You can purchase shares of Medifast, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Medifast, Inc. shares.
-
What Is The Medifast, Inc. Share Price Today?
Medifast, Inc. was last trading at $10.69 per share. This represents the most recent stock quote for Medifast, Inc.. Yesterday, Medifast, Inc. closed at $10.71 per share.
-
How To Buy Medifast, Inc. Stock Online?
In order to purchase Medifast, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MED Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MED
Sector
P/E ratio
516.75x
17.34x
PEG ratio
--
0.11x
P/B ratio
0.59x
1.51x
Price / LTM sales
0.31x
0.52x
Growth Metrics
MED
Sector
Revenue growth
-36.9%
2.88%
Earnings growth
-2361.32%
2.02%
Revenue (5-year growth)
-16.22%
3.56%
Earnings forecast
-$0.82
$0.23
Profitability
MED
Sector
Profitability FY 2025
$275.2M
$221.2M
Return on invested capital
-8.36%
4.24%
Return on assets
-6.83%
3.01%
Return on equity
-8.89%
7.77%
Earnings Date
Last Earnings Date
Feb
17
Next Earnings Date
Apr
27
Estimated Next Earnings Date
May
19
Balance Sheet
MED
Sector
Total cash
$167.3M
$87.3M
Short term investments
$71.4M
$31.1M
Total assets
$257M
$1.1B
Long term debt
$6.1M
$5.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 5.82% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 3.58% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.16% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
